Alpha 2.0
Login Register
» Articles » PMID: 14648032

A Randomized Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy with Imatinib (Glivec, Formerly STI571) in Comparison with Standard Induction Chemotherapy in Elderly (>55 Years) Patients with Philadelphia...

Overview
Journal Ann Hematol
Specialty Hematology
Date 2003 Dec 3
PMID 14648032
Citations 4
Authors
B Wassmann
N Gokbuget
U J Scheuring
A Binckebanck
R Reutzel
H Gschaidmeier
D Hoelzer
O G Ottmann
Affiliations
Soon will be listed here.
Citing Articles

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.

Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C Blood Adv. 2021; 6(6):1742-1753.

PMID: 34649276 PMC: 8941470. DOI: 10.1182/bloodadvances.2021004821.

Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.

Couban S, Savoie L, Mourad Y, Leber B, Minden M, Turner R Curr Oncol. 2014; 21(2):e265-309.

PMID: 24764712 PMC: 3997460. DOI: 10.3747/co.21.1834.

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Fielding A, Zakout G Curr Hematol Malig Rep. 2013; 8(2):98-108.

PMID: 23475624 DOI: 10.1007/s11899-013-0155-4.

Diagnostic molecular pathology, part 2: proteomics and clinical applications of molecular diagnostics in hematopathology.

Netto G, Saad R Proc (Bayl Univ Med Cent). 2005; 18(1):7-12.

PMID: 16200142 PMC: 1200694. DOI: 10.1080/08998280.2005.11928025.